Definition
Iduronate 2 Sulfatase (IDS), also known as Alpha L-Iduronate Sulfate Sulfatase or Idursulfase, is an enzyme essential for the breakdown of glycosaminoglycans (GAGs) like dermatan sulfate and heparan sulfate. It is encoded by the IDS gene, and its deficiency leads to a condition known as Hunter Syndrome (or Mucopolysaccharidosis II), a rare genetic disorder characterized by the accumulation of GAGs in tissues and organs, causing progressive damage.
In medical terms, Iduronate 2 Sulfatase (IDS) is used in enzyme replacement therapy (ERT) for treating Hunter Syndrome. The condition affects both males and females, although it is far more common in males due to its X-linked recessive inheritance pattern. The development and approval of treatments that provide functional IDS are crucial for managing this disorder, and the ongoing research in this space has paved the way for promising therapies that are designed to replace or supplement the deficient enzyme in patients.
The Iduronate 2 Sulfatase market refers to the market for drugs and therapies related to the management of Hunter Syndrome, including enzyme replacement therapies like Idursulfase (marketed as Elaprase). This market is heavily influenced by advancements in rare disease treatments, specifically those that target enzyme deficiencies such as the one caused by IDS deficiency.
Market Size
The Iduronate 2 Sulfatase (IDS) market was valued at USD 914 million in 2023 and is projected to reach USD 1,405.81 million by 2032, exhibiting a Compound Annual Growth Rate (CAGR) of 4.90% during the forecast period from 2025 to 2032.
This growth reflects the increasing prevalence of Hunter Syndrome, heightened awareness around rare diseases, and the development of more effective treatment options. Additionally, the market is benefitting from improved diagnostics and more accessible healthcare frameworks in emerging markets.
Historically, the market has been driven by the strong adoption of enzyme replacement therapies, with Idursulfase being the leading therapeutic solution. However, ongoing research into gene therapies and next-generation treatments is expected to open new avenues for growth. As the number of diagnosed cases increases due to better screening and awareness, the demand for effective treatments is projected to rise.
Market Dynamics
Drivers
-
Rising Prevalence of Hunter Syndrome The increasing global awareness of rare genetic disorders like Hunter Syndrome is a significant driver for the Iduronate 2 Sulfatase market. As more people are diagnosed due to advances in genetic testing and screening, the demand for targeted treatments like enzyme replacement therapy is expanding.
-
Approval and Adoption of Innovative Therapies The approval of Idursulfase (Elaprase) and other enzyme replacement therapies has significantly bolstered the market. With the growing number of treatments aimed at addressing the underlying genetic causes of Hunter Syndrome, such as gene therapy and substrate reduction therapy, the market is experiencing an uptick in innovation and availability of therapies.
-
Increased Investment in Rare Disease Research Pharmaceutical companies and research institutions are investing more in rare disease research. This focus has led to a greater understanding of the pathophysiology of Hunter Syndrome and the development of targeted therapies, which in turn drives market growth.
-
Government Support and Healthcare Initiatives The increasing recognition of the importance of rare disease treatments by governments worldwide has also contributed to the market's growth. Public healthcare policies in many regions now focus on expanding access to rare disease treatments and incentivizing innovation in orphan drug development.
Restraints
-
High Treatment Costs One of the major barriers to market growth is the high cost associated with enzyme replacement therapies and the relatively expensive treatment regimens for Hunter Syndrome. The costs of these therapies can be prohibitive for patients, particularly in low- and middle-income countries, which could hinder broader adoption.
-
Limited Market Size Since Hunter Syndrome is a rare disease, the number of patients is limited. This poses a challenge for pharmaceutical companies in terms of the market size, especially considering the high research and development costs associated with developing treatments for rare diseases.
-
Long Treatment Duration Treatments like Idursulfase typically require long-term or lifetime administration, which can be challenging for patients and families. Additionally, the long-term effectiveness of enzyme replacement therapies needs continuous evaluation, which may present further challenges in terms of patient compliance.
Opportunities
-
Gene Therapy and Advanced Biotechnologies The emerging field of gene therapy holds significant promise for the treatment of Hunter Syndrome. With advancements in gene-editing technologies like CRISPR, companies are exploring the possibility of curative treatments. These innovations open new opportunities for market expansion.
-
Expanding Access to Treatment in Emerging Markets Many emerging markets are increasingly prioritizing rare disease treatments, especially with support from international health organizations and governments. As healthcare infrastructure improves globally, particularly in Asia-Pacific and Latin America, there will be greater access to life-saving treatments for patients with Hunter Syndrome.
-
Pipeline Therapies Several new drug candidates targeting Iduronate 2 Sulfatase deficiency are currently in the pipeline, offering the potential for improved efficacy, patient compliance, and cost-effectiveness. These therapies may challenge existing market leaders, such as Idursulfase, and offer new hope for patients.
Challenges
-
Diagnostic Limitations One of the challenges for the Iduronate 2 Sulfatase market is the often delayed or misdiagnosis of Hunter Syndrome. As a rare genetic disorder, it is frequently underdiagnosed, particularly in regions without comprehensive genetic testing. Early diagnosis is critical for the timely initiation of treatment and improving patient outcomes.
-
Regulatory and Reimbursement Barriers Regulatory approval for new therapies can be a lengthy and complicated process, especially for rare diseases. Additionally, reimbursement for expensive treatments may be difficult to secure, particularly in countries with limited healthcare resources.
Regional Analysis
North America
North America holds the largest share of the Iduronate 2 Sulfatase market, primarily driven by the presence of Elaprase (Idursulfase) and other enzyme replacement therapies. The United States and Canada have well-established healthcare systems that facilitate the diagnosis and treatment of rare diseases like Hunter Syndrome. Additionally, government support and favorable reimbursement policies have boosted market growth in this region.
Europe
Europe is another key market for Iduronate 2 Sulfatase therapies, particularly in countries such as Germany, France, and the United Kingdom. The European Union’s Orphan Drug Regulations provide incentives for companies developing treatments for rare diseases, thus encouraging market players to invest in the development of therapies for Hunter Syndrome.
Asia-Pacific
The Asia-Pacific region is expected to experience the highest growth during the forecast period. The increasing availability of healthcare infrastructure, combined with rising awareness of rare diseases, is driving demand for treatments. China and India are emerging as key markets due to their large patient populations and increasing access to advanced healthcare.
Latin America and Middle East & Africa
In Latin America and Middle East & Africa, the market is expanding due to improving healthcare infrastructure and growing support for rare disease treatments. However, challenges related to treatment accessibility and affordability remain prevalent in these regions.
Competitor Analysis
Several pharmaceutical companies are leading the Iduronate 2 Sulfatase market, focusing on enzyme replacement therapies for Hunter Syndrome. Some key players in this market include:
-
Shire (Now part of Takeda Pharmaceutical Company) Shire developed Idursulfase (Elaprase), the most widely used therapy for Hunter Syndrome. Shire’s strong market presence and established product offerings position it as a dominant player.
-
Sanofi Genzyme Sanofi’s innovative approach in rare disease treatments has led to its involvement in therapies targeting mucopolysaccharidoses (MPS). The company is a key competitor in the enzyme replacement therapy market.
-
Ultragenyx Pharmaceutical Ultragenyx is a leading biotech company focused on developing treatments for rare diseases, including Hunter Syndrome. They are working on next-generation therapies for MPS II.
Global Iduronate 2 Sulfatase (IDS): Market Segmentation Analysis
This report provides a deep insight into the global Iduronate 2 Sulfatase market, covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trends, niche markets, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader shape the competition within the industries and strategies for the competitive environment to enhance potential profit. Furthermore, it provides a simple framework for evaluating and assessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Iduronate 2 Sulfatase market. This report introduces in detail the market share, market performance, product situation, operation situation, etc., of the main players, helping the readers in the industry identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Iduronate 2 Sulfatase market in any manner.
Market Segmentation (by Application)
- Enzyme Replacement Therapy (ERT)
- Gene Therapy for Hunter Syndrome
- Symptomatic Treatment
Market Segmentation (by Type)
- Idursulfase (Elaprase)
- Alternative Enzyme Therapies
- Pipeline Candidates (Gene Therapy, Enzyme Replacement)
Key Company
- Shire (Takeda Pharmaceutical)
- Sanofi Genzyme
- Ultragenyx Pharmaceutical
Geographic Segmentation
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
FAQ
1.What is the current market size of the Iduronate 2 Sulfatase market?
- The current market size is USD 914 million in 2023.
2.Which are the key companies operating in the Iduronate 2 Sulfatase market?
- Key companies include Shire (Takeda Pharmaceutical), Sanofi Genzyme, and Ultragenyx Pharmaceutical.
3.What are the key growth drivers in the Iduronate 2 Sulfatase market?
- Key drivers include rising prevalence of Hunter Syndrome, innovative therapies, and increased investment in rare disease research.
4.Which regions dominate the Iduronate 2 Sulfatase market?
- North America and Europe dominate the market, with Asia-Pacific expected to see the highest growth.
5.What are the emerging trends in the Iduronate 2 Sulfatase market?
- Emerging trends include the development of gene therapies, next-generation enzyme replacement therapies, and expanded market access in emerging regions.
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Iduronate 2 Sulfatase
1.2 Key Market Segments
1.2.1 Iduronate 2 Sulfatase Segment by Type
1.2.2 Iduronate 2 Sulfatase Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Iduronate 2 Sulfatase Market Overview
2.1 Global Market Overview
2.1.1 Global Iduronate 2 Sulfatase Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Iduronate 2 Sulfatase Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Iduronate 2 Sulfatase Market Competitive Landscape
3.1 Global Iduronate 2 Sulfatase Sales by Manufacturers (2019-2025)
3.2 Global Iduronate 2 Sulfatase Revenue Market Share by Manufacturers (2019-2025)
3.3 Iduronate 2 Sulfatase Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Iduronate 2 Sulfatase Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Iduronate 2 Sulfatase Sales Sites, Area Served, Product Type
3.6 Iduronate 2 Sulfatase Market Competitive Situation and Trends
3.6.1 Iduronate 2 Sulfatase Market Concentration Rate
3.6.2 Global 5 and 10 Largest Iduronate 2 Sulfatase Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Iduronate 2 Sulfatase Industry Chain Analysis
4.1 Iduronate 2 Sulfatase Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Iduronate 2 Sulfatase Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Iduronate 2 Sulfatase Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Iduronate 2 Sulfatase Sales Market Share by Type (2019-2025)
6.3 Global Iduronate 2 Sulfatase Market Size Market Share by Type (2019-2025)
6.4 Global Iduronate 2 Sulfatase Price by Type (2019-2025)
7 Iduronate 2 Sulfatase Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Iduronate 2 Sulfatase Market Sales by Application (2019-2025)
7.3 Global Iduronate 2 Sulfatase Market Size (M USD) by Application (2019-2025)
7.4 Global Iduronate 2 Sulfatase Sales Growth Rate by Application (2019-2025)
8 Iduronate 2 Sulfatase Market Consumption by Region
8.1 Global Iduronate 2 Sulfatase Sales by Region
8.1.1 Global Iduronate 2 Sulfatase Sales by Region
8.1.2 Global Iduronate 2 Sulfatase Sales Market Share by Region
8.2 North America
8.2.1 North America Iduronate 2 Sulfatase Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Iduronate 2 Sulfatase Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Iduronate 2 Sulfatase Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Iduronate 2 Sulfatase Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Iduronate 2 Sulfatase Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Iduronate 2 Sulfatase Market Production by Region
9.1 Global Production of Iduronate 2 Sulfatase by Region (2019-2025)
9.2 Global Iduronate 2 Sulfatase Revenue Market Share by Region (2019-2025)
9.3 Global Iduronate 2 Sulfatase Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Iduronate 2 Sulfatase Production
9.4.1 North America Iduronate 2 Sulfatase Production Growth Rate (2019-2025)
9.4.2 North America Iduronate 2 Sulfatase Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Iduronate 2 Sulfatase Production
9.5.1 Europe Iduronate 2 Sulfatase Production Growth Rate (2019-2025)
9.5.2 Europe Iduronate 2 Sulfatase Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Iduronate 2 Sulfatase Production (2019-2025)
9.6.1 Japan Iduronate 2 Sulfatase Production Growth Rate (2019-2025)
9.6.2 Japan Iduronate 2 Sulfatase Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Iduronate 2 Sulfatase Production (2019-2025)
9.7.1 China Iduronate 2 Sulfatase Production Growth Rate (2019-2025)
9.7.2 China Iduronate 2 Sulfatase Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 AngioChem
10.1.1 AngioChem Iduronate 2 Sulfatase Basic Information
10.1.2 AngioChem Iduronate 2 Sulfatase Product Overview
10.1.3 AngioChem Iduronate 2 Sulfatase Product Market Performance
10.1.4 AngioChem Business Overview
10.1.5 AngioChem Iduronate 2 Sulfatase SWOT Analysis
10.1.6 AngioChem Recent Developments
10.2 ArmaGen
10.2.1 ArmaGen Iduronate 2 Sulfatase Basic Information
10.2.2 ArmaGen Iduronate 2 Sulfatase Product Overview
10.2.3 ArmaGen Iduronate 2 Sulfatase Product Market Performance
10.2.4 ArmaGen Business Overview
10.2.5 ArmaGen Iduronate 2 Sulfatase SWOT Analysis
10.2.6 ArmaGen Recent Developments
10.3 Bioasis Technologies
10.3.1 Bioasis Technologies Iduronate 2 Sulfatase Basic Information
10.3.2 Bioasis Technologies Iduronate 2 Sulfatase Product Overview
10.3.3 Bioasis Technologies Iduronate 2 Sulfatase Product Market Performance
10.3.4 Bioasis Technologies Iduronate 2 Sulfatase SWOT Analysis
10.3.5 Bioasis Technologies Business Overview
10.3.6 Bioasis Technologies Recent Developments
10.4 Green Cross
10.4.1 Green Cross Iduronate 2 Sulfatase Basic Information
10.4.2 Green Cross Iduronate 2 Sulfatase Product Overview
10.4.3 Green Cross Iduronate 2 Sulfatase Product Market Performance
10.4.4 Green Cross Business Overview
10.4.5 Green Cross Recent Developments
10.5 JCR Pharmaceuticals
10.5.1 JCR Pharmaceuticals Iduronate 2 Sulfatase Basic Information
10.5.2 JCR Pharmaceuticals Iduronate 2 Sulfatase Product Overview
10.5.3 JCR Pharmaceuticals Iduronate 2 Sulfatase Product Market Performance
10.5.4 JCR Pharmaceuticals Business Overview
10.5.5 JCR Pharmaceuticals Recent Developments
10.6 Esteve
10.6.1 Esteve Iduronate 2 Sulfatase Basic Information
10.6.2 Esteve Iduronate 2 Sulfatase Product Overview
10.6.3 Esteve Iduronate 2 Sulfatase Product Market Performance
10.6.4 Esteve Business Overview
10.6.5 Esteve Recent Developments
10.7 RegenxBio
10.7.1 RegenxBio Iduronate 2 Sulfatase Basic Information
10.7.2 RegenxBio Iduronate 2 Sulfatase Product Overview
10.7.3 RegenxBio Iduronate 2 Sulfatase Product Market Performance
10.7.4 RegenxBio Business Overview
10.7.5 RegenxBio Recent Developments
10.8 Sangamo BioSciences
10.8.1 Sangamo BioSciences Iduronate 2 Sulfatase Basic Information
10.8.2 Sangamo BioSciences Iduronate 2 Sulfatase Product Overview
10.8.3 Sangamo BioSciences Iduronate 2 Sulfatase Product Market Performance
10.8.4 Sangamo BioSciences Business Overview
10.8.5 Sangamo BioSciences Recent Developments
10.9 Takeda
10.9.1 Takeda Iduronate 2 Sulfatase Basic Information
10.9.2 Takeda Iduronate 2 Sulfatase Product Overview
10.9.3 Takeda Iduronate 2 Sulfatase Product Market Performance
10.9.4 Takeda Business Overview
10.9.5 Takeda Recent Developments
11 Iduronate 2 Sulfatase Market Forecast by Region
11.1 Global Iduronate 2 Sulfatase Market Size Forecast
11.2 Global Iduronate 2 Sulfatase Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Iduronate 2 Sulfatase Market Size Forecast by Country
11.2.3 Asia Pacific Iduronate 2 Sulfatase Market Size Forecast by Region
11.2.4 South America Iduronate 2 Sulfatase Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Iduronate 2 Sulfatase by Country
12 Forecast Market by Type and by Application (2025-2032)
12.1 Global Iduronate 2 Sulfatase Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Iduronate 2 Sulfatase by Type (2025-2032)
12.1.2 Global Iduronate 2 Sulfatase Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Iduronate 2 Sulfatase by Type (2025-2032)
12.2 Global Iduronate 2 Sulfatase Market Forecast by Application (2025-2032)
12.2.1 Global Iduronate 2 Sulfatase Sales (K Units) Forecast by Application
12.2.2 Global Iduronate 2 Sulfatase Market Size (M USD) Forecast by Application (2025-2032)
13 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Iduronate 2 Sulfatase Market Size Comparison by Region (M USD)
Table 5. Global Iduronate 2 Sulfatase Sales (K Units) by Manufacturers (2019-2025)
Table 6. Global Iduronate 2 Sulfatase Sales Market Share by Manufacturers (2019-2025)
Table 7. Global Iduronate 2 Sulfatase Revenue (M USD) by Manufacturers (2019-2025)
Table 8. Global Iduronate 2 Sulfatase Revenue Share by Manufacturers (2019-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Iduronate 2 Sulfatase as of 2022)
Table 10. Global Market Iduronate 2 Sulfatase Average Price (USD/Unit) of Key Manufacturers (2019-2025)
Table 11. Manufacturers Iduronate 2 Sulfatase Sales Sites and Area Served
Table 12. Manufacturers Iduronate 2 Sulfatase Product Type
Table 13. Global Iduronate 2 Sulfatase Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Iduronate 2 Sulfatase
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Iduronate 2 Sulfatase Market Challenges
Table 22. Global Iduronate 2 Sulfatase Sales by Type (K Units)
Table 23. Global Iduronate 2 Sulfatase Market Size by Type (M USD)
Table 24. Global Iduronate 2 Sulfatase Sales (K Units) by Type (2019-2025)
Table 25. Global Iduronate 2 Sulfatase Sales Market Share by Type (2019-2025)
Table 26. Global Iduronate 2 Sulfatase Market Size (M USD) by Type (2019-2025)
Table 27. Global Iduronate 2 Sulfatase Market Size Share by Type (2019-2025)
Table 28. Global Iduronate 2 Sulfatase Price (USD/Unit) by Type (2019-2025)
Table 29. Global Iduronate 2 Sulfatase Sales (K Units) by Application
Table 30. Global Iduronate 2 Sulfatase Market Size by Application
Table 31. Global Iduronate 2 Sulfatase Sales by Application (2019-2025) & (K Units)
Table 32. Global Iduronate 2 Sulfatase Sales Market Share by Application (2019-2025)
Table 33. Global Iduronate 2 Sulfatase Sales by Application (2019-2025) & (M USD)
Table 34. Global Iduronate 2 Sulfatase Market Share by Application (2019-2025)
Table 35. Global Iduronate 2 Sulfatase Sales Growth Rate by Application (2019-2025)
Table 36. Global Iduronate 2 Sulfatase Sales by Region (2019-2025) & (K Units)
Table 37. Global Iduronate 2 Sulfatase Sales Market Share by Region (2019-2025)
Table 38. North America Iduronate 2 Sulfatase Sales by Country (2019-2025) & (K Units)
Table 39. Europe Iduronate 2 Sulfatase Sales by Country (2019-2025) & (K Units)
Table 40. Asia Pacific Iduronate 2 Sulfatase Sales by Region (2019-2025) & (K Units)
Table 41. South America Iduronate 2 Sulfatase Sales by Country (2019-2025) & (K Units)
Table 42. Middle East and Africa Iduronate 2 Sulfatase Sales by Region (2019-2025) & (K Units)
Table 43. Global Iduronate 2 Sulfatase Production (K Units) by Region (2019-2025)
Table 44. Global Iduronate 2 Sulfatase Revenue (US$ Million) by Region (2019-2025)
Table 45. Global Iduronate 2 Sulfatase Revenue Market Share by Region (2019-2025)
Table 46. Global Iduronate 2 Sulfatase Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 47. North America Iduronate 2 Sulfatase Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 48. Europe Iduronate 2 Sulfatase Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 49. Japan Iduronate 2 Sulfatase Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 50. China Iduronate 2 Sulfatase Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 51. AngioChem Iduronate 2 Sulfatase Basic Information
Table 52. AngioChem Iduronate 2 Sulfatase Product Overview
Table 53. AngioChem Iduronate 2 Sulfatase Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 54. AngioChem Business Overview
Table 55. AngioChem Iduronate 2 Sulfatase SWOT Analysis
Table 56. AngioChem Recent Developments
Table 57. ArmaGen Iduronate 2 Sulfatase Basic Information
Table 58. ArmaGen Iduronate 2 Sulfatase Product Overview
Table 59. ArmaGen Iduronate 2 Sulfatase Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 60. ArmaGen Business Overview
Table 61. ArmaGen Iduronate 2 Sulfatase SWOT Analysis
Table 62. ArmaGen Recent Developments
Table 63. Bioasis Technologies Iduronate 2 Sulfatase Basic Information
Table 64. Bioasis Technologies Iduronate 2 Sulfatase Product Overview
Table 65. Bioasis Technologies Iduronate 2 Sulfatase Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 66. Bioasis Technologies Iduronate 2 Sulfatase SWOT Analysis
Table 67. Bioasis Technologies Business Overview
Table 68. Bioasis Technologies Recent Developments
Table 69. Green Cross Iduronate 2 Sulfatase Basic Information
Table 70. Green Cross Iduronate 2 Sulfatase Product Overview
Table 71. Green Cross Iduronate 2 Sulfatase Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 72. Green Cross Business Overview
Table 73. Green Cross Recent Developments
Table 74. JCR Pharmaceuticals Iduronate 2 Sulfatase Basic Information
Table 75. JCR Pharmaceuticals Iduronate 2 Sulfatase Product Overview
Table 76. JCR Pharmaceuticals Iduronate 2 Sulfatase Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 77. JCR Pharmaceuticals Business Overview
Table 78. JCR Pharmaceuticals Recent Developments
Table 79. Esteve Iduronate 2 Sulfatase Basic Information
Table 80. Esteve Iduronate 2 Sulfatase Product Overview
Table 81. Esteve Iduronate 2 Sulfatase Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 82. Esteve Business Overview
Table 83. Esteve Recent Developments
Table 84. RegenxBio Iduronate 2 Sulfatase Basic Information
Table 85. RegenxBio Iduronate 2 Sulfatase Product Overview
Table 86. RegenxBio Iduronate 2 Sulfatase Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 87. RegenxBio Business Overview
Table 88. RegenxBio Recent Developments
Table 89. Sangamo BioSciences Iduronate 2 Sulfatase Basic Information
Table 90. Sangamo BioSciences Iduronate 2 Sulfatase Product Overview
Table 91. Sangamo BioSciences Iduronate 2 Sulfatase Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 92. Sangamo BioSciences Business Overview
Table 93. Sangamo BioSciences Recent Developments
Table 94. Takeda Iduronate 2 Sulfatase Basic Information
Table 95. Takeda Iduronate 2 Sulfatase Product Overview
Table 96. Takeda Iduronate 2 Sulfatase Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 97. Takeda Business Overview
Table 98. Takeda Recent Developments
Table 99. Global Iduronate 2 Sulfatase Sales Forecast by Region (2025-2032) & (K Units)
Table 100. Global Iduronate 2 Sulfatase Market Size Forecast by Region (2025-2032) & (M USD)
Table 101. North America Iduronate 2 Sulfatase Sales Forecast by Country (2025-2032) & (K Units)
Table 102. North America Iduronate 2 Sulfatase Market Size Forecast by Country (2025-2032) & (M USD)
Table 103. Europe Iduronate 2 Sulfatase Sales Forecast by Country (2025-2032) & (K Units)
Table 104. Europe Iduronate 2 Sulfatase Market Size Forecast by Country (2025-2032) & (M USD)
Table 105. Asia Pacific Iduronate 2 Sulfatase Sales Forecast by Region (2025-2032) & (K Units)
Table 106. Asia Pacific Iduronate 2 Sulfatase Market Size Forecast by Region (2025-2032) & (M USD)
Table 107. South America Iduronate 2 Sulfatase Sales Forecast by Country (2025-2032) & (K Units)
Table 108. South America Iduronate 2 Sulfatase Market Size Forecast by Country (2025-2032) & (M USD)
Table 109. Middle East and Africa Iduronate 2 Sulfatase Consumption Forecast by Country (2025-2032) & (Units)
Table 110. Middle East and Africa Iduronate 2 Sulfatase Market Size Forecast by Country (2025-2032) & (M USD)
Table 111. Global Iduronate 2 Sulfatase Sales Forecast by Type (2025-2032) & (K Units)
Table 112. Global Iduronate 2 Sulfatase Market Size Forecast by Type (2025-2032) & (M USD)
Table 113. Global Iduronate 2 Sulfatase Price Forecast by Type (2025-2032) & (USD/Unit)
Table 114. Global Iduronate 2 Sulfatase Sales (K Units) Forecast by Application (2025-2032)
Table 115. Global Iduronate 2 Sulfatase Market Size Forecast by Application (2025-2032) & (M USD)
List of Figures
Figure 1. Product Picture of Iduronate 2 Sulfatase
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Iduronate 2 Sulfatase Market Size (M USD), 2019-2032
Figure 5. Global Iduronate 2 Sulfatase Market Size (M USD) (2019-2032)
Figure 6. Global Iduronate 2 Sulfatase Sales (K Units) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Iduronate 2 Sulfatase Market Size by Country (M USD)
Figure 11. Iduronate 2 Sulfatase Sales Share by Manufacturers in 2023
Figure 12. Global Iduronate 2 Sulfatase Revenue Share by Manufacturers in 2023
Figure 13. Iduronate 2 Sulfatase Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Iduronate 2 Sulfatase Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Iduronate 2 Sulfatase Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Iduronate 2 Sulfatase Market Share by Type
Figure 18. Sales Market Share of Iduronate 2 Sulfatase by Type (2019-2025)
Figure 19. Sales Market Share of Iduronate 2 Sulfatase by Type in 2023
Figure 20. Market Size Share of Iduronate 2 Sulfatase by Type (2019-2025)
Figure 21. Market Size Market Share of Iduronate 2 Sulfatase by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Iduronate 2 Sulfatase Market Share by Application
Figure 24. Global Iduronate 2 Sulfatase Sales Market Share by Application (2019-2025)
Figure 25. Global Iduronate 2 Sulfatase Sales Market Share by Application in 2023
Figure 26. Global Iduronate 2 Sulfatase Market Share by Application (2019-2025)
Figure 27. Global Iduronate 2 Sulfatase Market Share by Application in 2023
Figure 28. Global Iduronate 2 Sulfatase Sales Growth Rate by Application (2019-2025)
Figure 29. Global Iduronate 2 Sulfatase Sales Market Share by Region (2019-2025)
Figure 30. North America Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 31. North America Iduronate 2 Sulfatase Sales Market Share by Country in 2023
Figure 32. U.S. Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 33. Canada Iduronate 2 Sulfatase Sales (K Units) and Growth Rate (2019-2025)
Figure 34. Mexico Iduronate 2 Sulfatase Sales (Units) and Growth Rate (2019-2025)
Figure 35. Europe Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 36. Europe Iduronate 2 Sulfatase Sales Market Share by Country in 2023
Figure 37. Germany Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 38. France Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 39. U.K. Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 40. Italy Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 41. Russia Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 42. Asia Pacific Iduronate 2 Sulfatase Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Iduronate 2 Sulfatase Sales Market Share by Region in 2023
Figure 44. China Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 45. Japan Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 46. South Korea Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 47. India Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 48. Southeast Asia Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 49. South America Iduronate 2 Sulfatase Sales and Growth Rate (K Units)
Figure 50. South America Iduronate 2 Sulfatase Sales Market Share by Country in 2023
Figure 51. Brazil Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 52. Argentina Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 53. Columbia Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 54. Middle East and Africa Iduronate 2 Sulfatase Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Iduronate 2 Sulfatase Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 57. UAE Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 58. Egypt Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 59. Nigeria Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 60. South Africa Iduronate 2 Sulfatase Sales and Growth Rate (2019-2025) & (K Units)
Figure 61. Global Iduronate 2 Sulfatase Production Market Share by Region (2019-2025)
Figure 62. North America Iduronate 2 Sulfatase Production (K Units) Growth Rate (2019-2025)
Figure 63. Europe Iduronate 2 Sulfatase Production (K Units) Growth Rate (2019-2025)
Figure 64. Japan Iduronate 2 Sulfatase Production (K Units) Growth Rate (2019-2025)
Figure 65. China Iduronate 2 Sulfatase Production (K Units) Growth Rate (2019-2025)
Figure 66. Global Iduronate 2 Sulfatase Sales Forecast by Volume (2019-2032) & (K Units)
Figure 67. Global Iduronate 2 Sulfatase Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Iduronate 2 Sulfatase Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Iduronate 2 Sulfatase Market Share Forecast by Type (2025-2032)
Figure 70. Global Iduronate 2 Sulfatase Sales Forecast by Application (2025-2032)
Figure 71. Global Iduronate 2 Sulfatase Market Share Forecast by Application (2025-2032)
